LEXINGTON, Mass., July 27,
2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a
biotechnology company focused on the development of emavusertib, an
orally available, small molecule IRAK4 inhibitor for the treatment
of hematologic malignancies, today announced that the Company will
release its second quarter 2023 financial results on Thursday, August 3, 2023, after the close of U.S.
markets. Management will host a conference call on the same day at
4:30 p.m. ET.
To access the live conference call, please dial (888)-346-6389
from the United States or (412)-317-5252 from other
locations, shortly before 4:30 p.m. ET. The conference call
can also be accessed on the Curis website
at www.curis.com in the 'Investors' section. A replay of
the financial results conference call will be available on the
Curis website shortly after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development of
emavusertib, an orally available, small molecule IRAK4 inhibitor
for the treatment of hematologic malignancies. In 2015, Curis
entered into a collaboration with Aurigene in the areas of
immuno-oncology and precision oncology. As part of this
collaboration, Curis has exclusive licenses to oral small molecule
antagonists of immune checkpoints including the VISTA/PDL1
antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as
the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is
currently undergoing testing in the Phase 1/2 TakeAim Lymphoma
study in patients with hematologic malignancies, such as
non-Hodgkin's lymphoma and other B cell malignancies both as a
monotherapy and in combination with the BTK inhibitor ibrutinib,
and the Phase 1/2 TakeAim Leukemia study in patients with acute
myeloid leukemia and myelodysplastic syndrome, for which it has
received Orphan Drug Designation from the U.S. Food and Drug
Administration. In addition, Curis is engaged in a collaboration
with ImmuNext for development of CI-8993, a monoclonal anti-VISTA
antibody. Curis is also party to a collaboration with Genentech, a
member of the Roche Group, under which Genentech and Roche are
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis's website at
www.curis.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/curis-to-release-second-quarter-2023-financial-results-and-hold-conference-call-on-august-3-2023-301887903.html
SOURCE Curis, Inc.